1. Market Research
  2. > 4-Antibody AG - Product Pipeline Review - 2013

4-Antibody AG - Product Pipeline Review - 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 21 pages

4-Antibody AG - Product Pipeline Review - 2013


Summary


Global Market Direct’s pharmaceuticals report, “4-Antibody AG - Product Pipeline Review - 2013” provides data on the 4-Antibody AG’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, 4-Antibody AG’s corporate website, SEC filings, investor presentations and featured press releases, both from 4-Antibody AG and industry-specific third party sources, put together by Global Markets Direct’s team.


Scope


- 4-Antibody AG - Brief 4-Antibody AG overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of 4-Antibody AG human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of 4-Antibody AG with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the 4-Antibody AG’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.


Reasons to buy


- Evaluate 4-Antibody AG’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of 4-Antibody AG in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the 4-Antibody AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with 4-Antibody AG.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of 4-Antibody AG and identify potential opportunities in those areas.

Table Of Contents

4-Antibody AG - Product Pipeline Review - 2013
Table of Contents 2
List of Tables 3
List of Figures 3
4-Antibody AG Snapshot 4
4-Antibody AG Overview 4
Key Information 4
Key Facts 4
4-Antibody AG - Research and Development Overview 5
Key Therapeutic Areas 5
4-Antibody AG - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
4-Antibody AG - Pipeline Products Glance 9
4-Antibody AG - Early Stage Pipeline Products 9
Pre-Clinical Products/Combination Treatment Modalities 9
Discovery Products/Combination Treatment Modalities 10
4-Antibody AG - Drug Profiles 11
4Ab-028 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
Antibody Targeting GITR 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
Antibody Targeting OX40 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
Antibody Targeting TIM-3 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
CXCR3 Antibody 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
Drug For AutoImmune Disorders And Inflammation 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
4-Antibody AG - Pipeline Analysis 17
4-Antibody AG - Pipeline Products by Therapeutic Class 17
4-Antibody AG - Pipeline Products By Mechanism of Action 18
4-Antibody AG - Locations And Subsidiaries 19
Head Office 19
Appendix 20
Methodology 20
Coverage 20
Secondary Research 20
Primary Research 20
Expert Panel Validation 20
Contact Us 21
Disclaimer 21

List of Tables


4-Antibody AG, Key Information 4
4-Antibody AG, Key Facts 4
4-Antibody AG - Pipeline by Indication, 2013 6
4-Antibody AG - Pipeline by Stage of Development, 2013 7
4-Antibody AG - Monotherapy Products in Pipeline, 2013 8
4-Antibody AG - Pre-Clinical, 2013 9
4-Antibody AG - Discovery, 2013 10
4-Antibody AG - Pipeline By Therapeutic Class, 2013 17
4-Antibody AG - Pipeline Products By Mechanism of Action, 2013 18

List of Figures


4-Antibody AG - Pipeline by Indication, 2013 6
4-Antibody AG - Pipeline by Stage of Development, 2013 7
4-Antibody AG - Monotherapy Products in Pipeline, 2013 8
4-Antibody AG - Pipeline By Therapeutic Class, 2013 17
4-Antibody AG - Pipeline Products By Mechanism of Action, 2013 18

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.